Urologic Cancers

Patients with metastatic urothelial cancer receive first-line treatment with platinum-based chemotherapy and second-line treatment with a checkpoint inhibitor. There is currently no approved third-line therapy for this malignancy. The investigational antibody-drug conjugate enfortumab vedotin may be a good choice for third-line therapy, based on the results of a phase 2 clinical trial presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Lower Urinary Tract Symptoms and Bladder Cancer

By Rosemary Frei, MSc

Urologic Cancers

Severe urinary hesitancy may be associated with increased risk of bladder cancer, according to data analysis of more than 30,000 men. Researchers suggest that voiding dysfunction leads to extended contact time between potential carcinogens and the cells lining the bladder. Read More ›

Adherence to Guidelines May Boost Cost of Follow-up Care After Radical Cystectomy

By Rosemary Frei, MSc

Urologic Cancers

A new analysis suggests that adherence to guidelines for follow-up care in patients who have undergone a radical cystectomy may standardize care but may also increase expenditures compared with the cost of most current approaches, which are more conservative and deviate from existing guidelines. Read More ›

Choice of Hospital for Readmissions Influences Mortality Risk in Men with Urologic Cancer

By Chase Doyle

Urologic Cancers

Patients with urologic cancer who are readmitted after a surgery to a second hospital and not to their original hospital are more likely to have complications than patients readmitted to their original surgical hospital, according to findings presented at the 2015 Genitourinary Cancers Symposium. Read More ›

Urologic Cancers

September 2021, Vol 7, No 2

CONNECT